Comments for ONXX - Stockpickr! Your Source for Stock Ideas

Comments for ONXX

Added By	Comments	Type	Date Added
sonpham39	buying	Love	August 26, 2009
barrons3	"You might want to keep an eye on Gilead [GILD], Onyx [ONXX], Myriad [MYGN] and Orexigen [OREX], ahead of the JP Morgan healthcare conference on Jan. 12th," adds Mike Huckman.	Love	January 07, 2009
sarah z	From a recent Mad Money show: "I don't want you to sell this. Big pharma needs new drugs and Onyx has it. Onyx is a ticket to make money, not lose it."	Love	September 12, 2008
sarah z	From a recent Mad Money show: "I don't want you to sell this. Big pharma needs new drugs and Onyx has it. Onyx is a ticket to make money, not lose it."	Love	September 11, 2008
barrons2	Thapar and other analysts point to Onyx Pharmaceuticals (ONXX) as a potential target of Bayer. Onyx has a joint venture with the German pharmaceutical giant for Nexavar, which is used to treat kidney and liver cancers. "At some point, you could see Bayer wanting to control 100% of the assets," says Sustersic, who thinks that Bayer might pay as much as $65 per share. Nexavar is believed to have more upside, especially as it secures approval in other markets (it was recently given the green light by China as a liver-cancer treatment), and even more if it can be used for other cancers, including those of the breast, lungs and skin.	Love	August 16, 2008
barrons2	News of the Bristol-Meyers (BMY) offer to buy out ImClone (IMCL) deal triggered a flurry of option activity in Amgen (AMGN), Onyx Pharmaceuticals (ONXX), and Amylin (AMLN) said option strategist Frederic Ruffy.	Love	August 06, 2008
barrons2	Buy - Price 34.75 on June 23 by Broadpoint Capital CFO Greg Schafer resigned June 17 and will [depart] by Dec. 15...incrementally positive news for the stock (not a reflection on Schafer's ability), because we believe that it makes sense for new CEO Tony Coles to pick his own team....The most important piece of news, near term, [will be] announcement of Q208 Nexavar sales [for treating certain liver- and kidney-cancer patients] around July 30...We expect Nexavar sales will be significantly higher than most Street project[ions] and expect Onyx management will adjust its guidance for Nexavar sales for the year upward. Our 48 target appl[ies] a 30 times forward price/earnings multiple to our 2010 fully diluted EPS of $2.25. Market cap: $1.9 billion.	Love	June 28, 2008
stockerblog	oral anticancer therapies used to prevent cancer cell proliferation and angiogenesis	Love	May 10, 2008
chrisblank	I am taking a beating	Hate	March 03, 2008
larry23	dead wood	Hate	February 22, 2008
pyromatic96	POSSIBLE GROWTH	Love	January 04, 2008
Philconn	Speculative biotech play with (Nexavar) as a cancer drug that now has been approved for use in Europe for liver ca. Could be huge.	Love	November 24, 2007
barrons2	"Cramer's favorite biotech and the one he feels is the Amgen of 2008 is Onyx Pharmaceuticals (ONXX), a stock which hit its 52-week high on Nov. 7."	Love	November 15, 2007
tomvchris	not enough room under favorites	Hate	November 11, 2007
gringa	chart pattern says ready for movement upwards	Love	September 27, 2007
JOCKOBRATZI	BIO	Love	September 13, 2007
hallik	Penny Stock	Love	September 07, 2007
sarah z	Cramer was out with bullish comments on Onyx Pharmaceuticals Inc. (ONXX), calling the company's Nexavar drug "the next unbelievable blockbuster." Cramer had on the chairman and president of ONXX Hollings Renton to tell market players what is in store for the company. Renton agreed with Cramer that Nexavar is showing very big promise in trails for fighting liver cancer. Renton said that ONXX had $80 million in sales in the second quarter. Cramer said that Nexavar may turn out to be "the best cancer story ever told." Cramer also thinks a major player like Bayer (BAY) might want to buy ONXX. Cramer said look to buy the stock on dips.	Love	August 30, 2007
Ellen James	may go up quickly	Love	August 28, 2007
Primary278	Lost too much money twice - never touch it again - just emoitional	Hate	July 30, 2007
gcrisci	Cancer drug w/ hope	Love	July 26, 2007
jheffner	Cramer	Love	June 29, 2007
anoaeen	Nexavar drug to propel sales by year end, potential for takeover by Bayer	Love	June 18, 2007
djwong	Recommendation from Mad Money	Love	June 12, 2007
joe1807b	New drugs	Love	June 10, 2007
Brian Larson	A great case study on the effects of information/hype on a stock price.	Love	June 05, 2007
Frank Fen	Speculative - short term	Love	May 22, 2007
heater	speculative pharma	Love	May 11, 2007
pschiererd	Big release coming June 4th, stock is slumping now.	Love	May 10, 2007
Pumacom	My spec play... held up well after the huge run up, so I jumped in. Thinking Bayer might snatch it up. Cancer drug Nexavar is looking good, and earnings have been doing well. Lots of catalysts with this one.	Love	May 07, 2007